PNT Stock Overview
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
POINT Biopharma Global Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.50 |
| 52 Week High | US$14.35 |
| 52 Week Low | US$6.57 |
| Beta | -0.0026 |
| 1 Month Change | -9.49% |
| 3 Month Change | 87.41% |
| 1 Year Change | 75.07% |
| 3 Year Change | -10.20% |
| 5 Year Change | n/a |
| Change since IPO | 3.99% |
Recent News & Updates
Recent updates
POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates
Aug 20
We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth
Feb 01A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)
Oct 18Point Biopharma plummets on announcing common stock offering
Sep 13POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05
Aug 12Shareholder Returns
| PNT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | -3.6% | -2.4% |
| 1Y | 75.1% | -2.7% | 23.3% |
Return vs Industry: PNT exceeded the US Biotechs industry which returned 6% over the past year.
Return vs Market: PNT exceeded the US Market which returned 24.8% over the past year.
Price Volatility
| PNT volatility | |
|---|---|
| PNT Average Weekly Movement | 24.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PNT's share price has been volatile over the past 3 months.
Volatility Over Time: PNT's weekly volatility has increased from 13% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 129 | Joe McCann | www.pointbiopharma.com |
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies.
POINT Biopharma Global Inc. Fundamentals Summary
| PNT fundamental statistics | |
|---|---|
| Market cap | US$1.33b |
| Earnings (TTM) | US$96.55m |
| Revenue (TTM) | US$243.69m |
13.8x
P/E Ratio5.5x
P/S RatioIs PNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNT income statement (TTM) | |
|---|---|
| Revenue | US$243.69m |
| Cost of Revenue | US$0 |
| Gross Profit | US$243.69m |
| Other Expenses | US$147.14m |
| Earnings | US$96.55m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | 39.62% |
| Debt/Equity Ratio | 0% |
How did PNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/28 08:38 |
| End of Day Share Price | 2023/12/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
POINT Biopharma Global Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Charles Zhu | Guggenheim Securities, LLC |